[Obesity, inflammation and insulin resistance: role of gp 130 receptor ligands].
Obesity can be considered as a low grade inflammatory disease, characterized by increased plasma levels of proinflammatory cytokines such as tumoral necrosis factor-a (TNF-a), and acute phase reactant proteins like C-reactive protein. In this context, some cytokines of the interleukin-6 (IL-6) family have been involved in the inflammatory processes associated to obesity. In addition to IL-6, the IL-6 cytokine family includes IL-11, ciliary neurotrophic factor (cntf), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC), leukemia inhibitory factor (LIF) y Oncostatin M (OsM). These proteins are also known as gp130 cytokines because all of them exert their action via the glycoprotein 130 (gp130) as a common transducer protein within their functional receptor complexes. However, their role in obesity and related disorders is controversial; thus, whereas some studies have described the involvement of gp130 cytokines in the development of obesity and its related cluster of pathophysiologic conditions like insulin-resistance, fatty liver and cardiovascular diseases, other trials have proposed the gp130 receptor ligands as therapeutic targets in the treatment of obesity and its related disorders. In fact, CNTF treatment has demonstrated to be effective in the reduction of body weight, by promoting the inhibition of food intake and the activation of the energy expenditure, together with an improvement of insulin sensitivity. This review analyzes the potential therapeutic role of some of the gp130 ligands in obesity and related diseases.
Marcos-Gómez
B
B
Departamento de Ciencias de la Alimentación, Fisiología y Toxicología, Universidad de Navarra, Pamplona, Spain.
Bustos
M
M
Prieto
J
J
Martínez
J A
JA
Moreno-Aliaga
M J
MJ
D050822:Cytokine Receptor gp130 / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D007333:Insulin Resistance; D009765:Obesity / Q000378:metabolism*
D050822:Cytokine Receptor gp130